$2.05
1.49% yesterday
Nasdaq, Jan 06, 10:13 pm CET
ISIN
CA59935V1076
Symbol
MIST

Milestone Pharmaceuticals, Inc. Stock price

$2.05
-0.61 22.93% 1M
-0.12 5.53% 6M
+0.03 1.49% YTD
-0.14 6.39% 1Y
-1.83 47.16% 3Y
-4.80 70.07% 5Y
-12.95 86.33% 10Y
-12.95 86.33% 20Y
Nasdaq, Closing price Tue, Jan 06 2026
+0.03 1.49%
ISIN
CA59935V1076
Symbol
MIST
Industry

Key metrics

Basic
Market capitalization
$172.0m
Enterprise Value
$145.7m
Net debt
positive
Cash
$82.6m
Shares outstanding
85.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
8.4
Financial Health
Equity Ratio
17.4%
Return on Equity
-315.8%
ROCE
-74.1%
ROIC
-
Debt/Equity
2.7
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-57.1m | $-20.4m
EBIT
$-57.2m | $-61.4m
Net Income
$-58.0m | $-62.2m
Free Cash Flow
$-43.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-31.5% | 51.4%
EBIT
-31.4% | -45.8%
Net Income
-35.6% | -49.8%
Free Cash Flow
-35.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.6
FCF per Share
$-0.5
Short interest
9.7%
Employees
33
Rev per Employee
$0.0
Show more

Is Milestone Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,084 stocks worldwide.

Milestone Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:

8x Buy
73%
3x Hold
27%

Analyst Opinions

11 Analysts have issued a Milestone Pharmaceuticals, Inc. forecast:

Buy
73%
Hold
27%

Financial data from Milestone Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 41 41
47% 47%
-
- Research and Development Expense 17 17
3% 3%
-
-57 -57
31% 31%
-
- Depreciation and Amortization 0.11 0.11
10% 10%
-
EBIT (Operating Income) EBIT -57 -57
31% 31%
-
Net Profit -58 -58
36% 36%
-

In millions USD.

Don't miss a Thing! We will send you all news about Milestone Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Milestone Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
about 10 hours ago
European decision on approval is expected by Q1 2027 If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the healthcare setting MONTREAL and CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercia...
Neutral
Seeking Alpha
22 days ago
Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript
Neutral
GlobeNewsWire
25 days ago
First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT  Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT enables development of AFib-RVR under sNDA pathway Milestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financing Conference call and webcast December 15, ...
More Milestone Pharmaceuticals, Inc. News

Company Profile

Milestone Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. The firm designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.

Head office Canada
CEO Joseph Oliveto
Employees 33
Founded 2003
Website www.milestonepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today